RT Journal Article
SR Electronic
T1 Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.23.20041707
DO 10.1101/2020.03.23.20041707
A1 Lou, Bin
A1 Li, Ting-Dong
A1 Zheng, Shu-Fa
A1 Su, Ying-Ying
A1 Li, Zhi-Yong
A1 Liu, Wei
A1 Yu, Fei
A1 Ge, Sheng-Xiang
A1 Zou, Qian-Da
A1 Yuan, Quan
A1 Lin, Sha
A1 Hong, Cong-Ming
A1 Yao, Xiang-Yang
A1 Zhang, Xue-Jie
A1 Wu, Ding-Hui
A1 Zhou, Guo-Liang
A1 Hou, Wang-Heng
A1 Li, Ting-Ting
A1 Zhang, Ya-Li
A1 Zhang, Shi-Yin
A1 Fan, Jian
A1 Zhang, Jun
A1 Xia, Ning-Shao
A1 Chen, Yu
YR 2020
UL http://medrxiv.org/content/early/2020/03/27/2020.03.23.20041707.abstract
AB Background Timely diagnosis of SARS-CoV-2 infection is the prerequisite for treatment and preventive quarantine. The serology characteristics and complement diagnosis value of antibody test to RNA test needs to be demonstrated.Method A patient cohort study was conducted at the first affiliated hospital of Zhejiang University, China. Serial plasma of COVID-19 patients and were collected and total antibody (Ab), IgM and IgG antibody against SARS-CoV-2 were detected. The antibody dynamics during the infection were described.Results The seroconversion rate for Ab, IgM and IgG in COVID-19 patients was 98.8% (79/80), 93.8% (75/80) and 93.8% (75/80), respectively. The first detectible serology marker is total antibody and followed by IgM and IgG, with a median seroconversion time of 15, 18 and 20 day post exposure (d.p.e) or 9, 10 and 12 days post onset, separately. The antibody levels increased rapidly since 6 d.p.o and accompanied with the decline of viral load. For patients in the early stage of illness (0-7d.p.o),Ab showed the highest sensitivity (64.1%) compared to the IgM and IgG (33.3% for both, p<0.001). The sensitivities of Ab, IgM and IgG detection increased to 100%, 96.7% and 93.3% two weeks later, respectively.Conclusions Typical acute antibody response is induced during the SARS-CoV-2 infection. The serology testing provides important complementation to RNA test for pathogenic specific diagnosis and helpful information to evaluate the adapted immunity status of patient. It should be strongly recommended to apply well-validated antibody tests in the clinical management and public health practice to improve the control of COVID-19 infection.Take-Home Message Antibody responses are induced after SARS-CoV-2 infection and complement diagnosis value of antibody test to RNA test was observed. Antibody tests are critical tools in clinical management and control of SARS-CoV-2 infection and COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by China National Mega-Projects for Infectious Diseases (2017ZX10103008), and the Science and Technology Major Project of Xiamen (3502Z2020YJ01).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe will share individual participant data that underlie the results reported in this article after deidentification (text, tables, figures and appendices). The data will be available beginning 6 months after the major findings from the final analysis of the study were published, ending 2 years later. The data will be shared with investigators whose proposed use of the data has been approved by an independent review committee identified for individual participant data meta-analysis. Proposals should be directed to chenyuzy@zju.edu.cn. To gain access, data requestors will need to sign a data access agreement.